Michael D George1, Joshua F Baker2, Kevin Winthrop3, Jesse Y Hsu1, Qufei Wu1, Lang Chen4, Fenglong Xie4, Huifeng Yun4, Jeffrey R Curtis4. 1. University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania (M.D.G., J.Y.H., Q.W.). 2. University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania (J.F.B.). 3. Oregon Health & Science University, Portland, Oregon (K.W.). 4. University of Alabama at Birmingham, Birmingham, Alabama (L.C., F.X., H.Y., J.R.C.).
Abstract
BACKGROUND: Low-dose glucocorticoids are frequently used for the management of rheumatoid arthritis (RA) and other chronic conditions, but the safety of long-term use remains uncertain. OBJECTIVE: To quantify the risk for hospitalized infection with long-term use of low-dose glucocorticoids in patients with RA receiving stable disease-modifying antirheumatic drug (DMARD) therapy. DESIGN: Retrospective cohort study. SETTING: Medicare claims data and Optum's deidentified Clinformatics Data Mart database from 2006 to 2015. PATIENTS: Adults with RA receiving a stable DMARD regimen for more than 6 months. MEASUREMENTS: Associations between glucocorticoid dose (none, ≤5 mg/d, >5 to 10 mg/d, and >10 mg/d) and hospitalized infection were evaluated using inverse probability-weighted analyses, with 1-year cumulative incidence predicted from weighted models. RESULTS: 247 297 observations were identified among 172 041 patients in Medicare and 58 279 observations among 44 118 patients in Optum. After 6 months of stable DMARD use, 47.1% of Medicare patients and 39.5% of Optum patients were receiving glucocorticoids. The 1-year cumulative incidence of hospitalized infection in Medicare patients not receiving glucocorticoids was 8.6% versus 11.0% (95% CI, 10.6% to 11.5%) for glucocorticoid dose of 5 mg or less per day, 14.4% (CI, 13.8% to 15.1%) for greater than 5 to 10 mg/d, and 17.7% (CI, 16.5% to 19.1%) for greater than 10 mg/d (all P < 0.001 vs. no glucocorticoids). The 1-year cumulative incidence of hospitalized infection in Optum patients not receiving glucocorticoids was 4.0% versus 5.2% (CI, 4.7% to 5.8%) for glucocorticoid dose of 5 mg or less per day, 8.1% (CI, 7.0% to 9.3%) for greater than 5 to 10 mg/d, and 10.6% (CI, 8.5% to 13.2%) for greater than 10 mg/d (all P < 0.001 vs. no glucocorticoids). LIMITATION: Potential for residual confounding and misclassification of glucocorticoid dose. CONCLUSION: In patients with RA receiving stable DMARD therapy, glucocorticoids were associated with a dose-dependent increase in the risk for serious infection, with small but significant risks even at doses of 5 mg or less per day. Clinicians should balance the benefits of low-dose glucocorticoids with this potential risk. PRIMARY FUNDING SOURCE: National Institute of Arthritis and Musculoskeletal and Skin Diseases.
BACKGROUND: Low-dose glucocorticoids are frequently used for the management of rheumatoid arthritis (RA) and other chronic conditions, but the safety of long-term use remains uncertain. OBJECTIVE: To quantify the risk for hospitalized infection with long-term use of low-dose glucocorticoids in patients with RA receiving stable disease-modifying antirheumatic drug (DMARD) therapy. DESIGN: Retrospective cohort study. SETTING: Medicare claims data and Optum's deidentified Clinformatics Data Mart database from 2006 to 2015. PATIENTS: Adults with RA receiving a stable DMARD regimen for more than 6 months. MEASUREMENTS: Associations between glucocorticoid dose (none, ≤5 mg/d, >5 to 10 mg/d, and >10 mg/d) and hospitalized infection were evaluated using inverse probability-weighted analyses, with 1-year cumulative incidence predicted from weighted models. RESULTS: 247 297 observations were identified among 172 041 patients in Medicare and 58 279 observations among 44 118 patients in Optum. After 6 months of stable DMARD use, 47.1% of Medicare patients and 39.5% of Optumpatients were receiving glucocorticoids. The 1-year cumulative incidence of hospitalized infection in Medicare patients not receiving glucocorticoids was 8.6% versus 11.0% (95% CI, 10.6% to 11.5%) for glucocorticoid dose of 5 mg or less per day, 14.4% (CI, 13.8% to 15.1%) for greater than 5 to 10 mg/d, and 17.7% (CI, 16.5% to 19.1%) for greater than 10 mg/d (all P < 0.001 vs. no glucocorticoids). The 1-year cumulative incidence of hospitalized infection in Optumpatients not receiving glucocorticoids was 4.0% versus 5.2% (CI, 4.7% to 5.8%) for glucocorticoid dose of 5 mg or less per day, 8.1% (CI, 7.0% to 9.3%) for greater than 5 to 10 mg/d, and 10.6% (CI, 8.5% to 13.2%) for greater than 10 mg/d (all P < 0.001 vs. no glucocorticoids). LIMITATION: Potential for residual confounding and misclassification of glucocorticoid dose. CONCLUSION: In patients with RA receiving stable DMARD therapy, glucocorticoids were associated with a dose-dependent increase in the risk for serious infection, with small but significant risks even at doses of 5 mg or less per day. Clinicians should balance the benefits of low-dose glucocorticoids with this potential risk. PRIMARY FUNDING SOURCE: National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Authors: Marieke Dingena Spreeuwenberg; Anna Bartak; Marcel A Croon; Jacques A Hagenaars; Jan J V Busschbach; Helene Andrea; Jos Twisk; Theo Stijnen Journal: Med Care Date: 2010-02 Impact factor: 2.983
Authors: Björn Svensson; Annelies Boonen; Kristina Albertsson; Désirée van der Heijde; Catharina Keller; Ingiäld Hafström Journal: Arthritis Rheum Date: 2005-11
Authors: Carlos G Grijalva; Lang Chen; Elizabeth Delzell; John W Baddley; Timothy Beukelman; Kevin L Winthrop; Marie R Griffin; Lisa J Herrinton; Liyan Liu; Rita Ouellet-Hellstrom; Nivedita M Patkar; Daniel H Solomon; James D Lewis; Fenglong Xie; Kenneth G Saag; Jeffrey R Curtis Journal: JAMA Date: 2011-11-06 Impact factor: 56.272
Authors: Grant W Cannon; Ted R Mikuls; Candace L Hayden; Jian Ying; Jeffrey R Curtis; Andreas M Reimold; Liron Caplan; Gail S Kerr; J Steuart Richards; Dannette S Johnson; Brian C Sauer Journal: Arthritis Care Res (Hoboken) Date: 2011-12 Impact factor: 4.794
Authors: Yannick Palmowski; Thomas Buttgereit; Christian Dejaco; Johannes W Bijlsma; Eric L Matteson; Marieke Voshaar; Maarten Boers; Frank Buttgereit Journal: Arthritis Care Res (Hoboken) Date: 2017-07-10 Impact factor: 4.794
Authors: Garifallia Sakellariou; Carlo Alberto Scirè; Federica Rumi; Greta Carrara; Anna Zanetti; Carlo Cerra; Simona Migliazza; Serena Bugatti; Carlomaurizio Montecucco Journal: Arthritis Res Ther Date: 2022-06-16 Impact factor: 5.606
Authors: Víctor Moreno-Torres; Carmen de Mendoza; Sara de la Fuente; Enrique Sánchez; María Martínez-Urbistondo; Jesús Herráiz; Andrea Gutiérrez; Ángela Gutiérrez; Carlos Hernández; Alejandro Callejas; Carmen Maínez; Ana Royuela; Valentín Cuervas-Mons Journal: Intern Emerg Med Date: 2021-08-18 Impact factor: 5.472
Authors: Michael D George; Jesse Y Hsu; Sean Hennessy; Lang Chen; Fenglong Xie; Jeffrey R Curtis; Joshua F Baker Journal: Epidemiology Date: 2022-01-01 Impact factor: 4.822
Authors: Bryant R England; Punyasha Roul; Yangyuna Yang; Andre C Kalil; Kaleb Michaud; Geoffrey M Thiele; Brian C Sauer; Joshua F Baker; Ted R Mikuls Journal: Arthritis Rheumatol Date: 2021-10-19 Impact factor: 15.483
Authors: Tue Wenzel Kragstrup; Bente Glintborg; Annemarie L Svensson; Christopher McMaster; Philip C Robinson; Bent Deleuran; David Fl Liew Journal: RMD Open Date: 2022-02
Authors: M Elaine Husni; Atul Deodhar; Sergio Schwartzman; Soumya D Chakravarty; Elizabeth C Hsia; Jocelyn H Leu; Yiying Zhou; Kim H Lo; Arthur Kavanaugh Journal: Arthritis Res Ther Date: 2022-03-21 Impact factor: 5.156
Authors: Beth I Wallace; Meriah N Moore; Andrew C Heisler; Lutfiyya N Muhammad; Jing Song; Daniel J Clauw; Clifton O Bingham; Marcy B Bolster; Wendy Marder; Tuhina Neogi; Alyssa Wohlfahrt; Dorothy D Dunlop; Yvonne C Lee Journal: Rheumatology (Oxford) Date: 2022-04-11 Impact factor: 7.046
Authors: Lisa K Stamp; Hamish Farquhar; Huai Leng Pisaniello; Ana B Vargas-Santos; Mark Fisher; David B Mount; Hyon K Choi; Robert Terkeltaub; Catherine L Hill; Angelo L Gaffo Journal: Nat Rev Rheumatol Date: 2021-07-30 Impact factor: 20.543